| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 70.298 | 73.693 | 86.493 | 100.923 | 107.516 | 80.406 | 147.502 | 187.814 | 205.373 | 276.238 |
| Total Income - EUR | 70.298 | 73.693 | 86.493 | 100.923 | 107.516 | 87.416 | 160.544 | 207.828 | 262.026 | 312.967 |
| Total Expenses - EUR | 70.231 | 73.622 | 84.527 | 99.649 | 105.156 | 93.516 | 156.905 | 204.928 | 257.865 | 285.786 |
| Gross Profit/Loss - EUR | 67 | 71 | 1.965 | 1.274 | 2.361 | -6.100 | 3.639 | 2.901 | 4.161 | 27.181 |
| Net Profit/Loss - EUR | 56 | 59 | 1.167 | 265 | 1.285 | -6.974 | 2.034 | 824 | 1.888 | 22.919 |
| Employees | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 6 | 11 | 5 |
Check the financial reports for the company - Salix Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 21.540 | 20.300 | 20.264 | 19.708 | 21.166 |
| Current Assets | 20.810 | 19.163 | 27.222 | 26.976 | 19.973 | 60.876 | 51.237 | 71.410 | 48.713 | 77.227 |
| Inventories | 12.532 | 11.164 | 12.769 | 10.216 | 5.413 | 29.221 | 13.462 | 30.944 | 28.602 | 59.668 |
| Receivables | 6.494 | 2.789 | 13.125 | 15.825 | 11.617 | 29.385 | 26.746 | 29.298 | 11.876 | 9.983 |
| Cash | 1.784 | 5.211 | 1.328 | 936 | 2.943 | 2.270 | 11.029 | 11.167 | 8.235 | 7.577 |
| Shareholders Funds | 45 | 44 | 44 | 43 | 42 | -6.870 | -4.684 | -3.875 | -1.975 | 20.956 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 0 | 0 | 0 | 0 | 0 |
| Debts | 22.970 | 21.547 | 29.565 | 27.564 | 19.931 | 89.285 | 76.221 | 95.548 | 70.395 | 77.437 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Salix Pharm Srl